A recently approved antibody drug from Regeneron Pharmaceuticals eradicates residual traces of multiple myeloma after initial ...

Regeneron is finding ways to deal with the increased competition to one of its key growth drivers. The company is also ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

The Investment Committee debate the latest Calls of the Day. Lawmakers react to US seizure of Venezuelan oil tanker 'Taylor ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Regeneron said on Saturday its experimental cancer combination therapy was effective and showed disappearance of the disease ...

From a technical perspective, Regeneron (REGN) is looking like an interesting pick, as it just reached a key level of support. REGN recently overtook the 20-day moving average, and this suggests a ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...